Drug Topics e-News:

Having trouble viewing this email? View in a browser.

You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.

Subscribe Now

to Drug Topics e-News

Drug Topics, Voice of the Pharmacist
Part of the Modern Medicine Network

e-News

DrugTopics.com

February 24, 2011

Drug Topics
Home CE DT Blog JP at Large Viewpoints Regulatory and Legal Archives
In This Issue
Oseltamivir back-ordered
DT Blog: Plan B
Makena approved
Bone drugs linked to decrease in colon cancer
Terbutaline linked to cardio risks in pregnancy
Rosiglitazone linked to cardio risks
Continuing Education
Newest: Medication errors: Causes, prevention, liability, and the apology
For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here
Meetings
Survey
This month we would like to know...

As a pharmacist, do you ever advise patients to split pills to save on costs?
* Yes

* No
Click Here to Vote

Digital Edition

Drug Topics Digital Edition View Current Edition Subscribe to the Digital Edition

Oseltamivir oral suspension back-ordered due to increased demand

Supplies of oseltamivir oral suspension (Tamiflu) are not yet depleted at wholesalers and pharmacies, despite the drug being placed on back order due to increased demand. Read full article.

divider

DT Blog

Melissa

A discussion generated by Drug Topics’ readers, editorial staff, and advisory board
Melissa Stahlecker, PharmD, Acute Care Pharmacist, Rapid City, S.D.

Another look at Plan B Read full article.

divider

FDA approves drug to prevent premature births

FDA has approved the first drug to help prevent premature delivery before 37 weeks in women who have had at least 1 previous preterm birth. Read full article.

divider

Bone-loss drugs may reduce colon-cancer risk

Bisphosphonates such as Fosamax and Boniva may reduce patients' risk of developing colon cancer, according to a new study published in the Journal of Clinical Oncology. Read full article.

divider

FDA warns against terbutaline use by pregnant women

FDA notified healthcare professionals that neither injectable nor oral terbutaline be used by pregnant women for prevention of preterm labor due to risk of serious maternal heart problems and death. Read full article.

divider

Rosiglitazone labels update cardiovascular risks

Labeling for rosiglitazone (Avandia, GlaxoSmithKline) has been changed to include information on cardiovascular risks connected with use of this agent. Read full article.

divider

Meetings and Events

March 9-10, 2011 NACDS RxIMPACT Day on Capitol Hill
Washington, DC
Contact:
P.O. Box 34814
Alexandria, VA 22334-0814
hecker@nacds.org

March 13-15, 2011 NACDS Supply Chain & Logistics Conference
San Diego, CA
Contact:
P.O. Box 34814
Alexandria, VA 22334-0814
703-683-5678

March 14-17, 2011 The 35th International Good Manufacturing Practices Conference
On spotlighting GMP enforcement
Athens, GA
Contact:
Gary Dykstra
678-985-6827
gdykstra@rx.uga.edu

March 25-28, 2011 American Pharmacists Annual Meeting
Seattle, WA
Contact:
2215 Constitution Avenue, NW
Washington, DC 20037
Phone: 1-800-237-2742 (APhA)
Fax: 202-448-8734

CEC

Connect to Us

Twitter Follow Us on Twitter
Congratulations to Shawn Ackerman, Walgreens, Bristol, R.I., for winning the $100 gift card for participating in the January Drug Topics' reader survey.
Contact Us Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Healthcare

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.